Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma

Rare disease drug developer Ovid Therapeutics is slated to reveal Phase 3 data from its lead program, a potential treatment for Angelman syndrome, by year’s end. If the drug is approved, the privately held Italian company Angelini Pharma will carry it forward for that indication in the Europe Union and a handful of other countries.